TSX Exchange Symbol: RVX
CALGARY, Oct. 17 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)
announced today that the Toronto Stock Exchange has approved Resverlogix's
previous announcement on October 15, 2008 regarding the redeeming of
US $10 million of its remaining US $17.3 million debenture. The remaining
balance of the debenture including accrued interest earned to October 14, 2008
is US $7.89 million.
To assist shareholders with understanding the salient and beneficial
points to this amendment Resverlogix will post key facts to SEDAR.
Rodman & Renshaw, LLC served as an advisor to the company.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Kelly McNeill, Chief Financial Officer, Resverlogix
Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Kelly@resverlogix.com, Website: www.resverlogix.com